SCHEMBL6099398

SCHEMBL6099398

COc1cc(CC(=O)Nc2cccc(CCc3ccccc3)c2)ccc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
LMNA P02545 2/20 0.64
HTT P42858 2/20 0.64
USP2 O75604 1/20 0.57
TRPV1 Q8NER1 1/20 0.56
STAT3 P40763 1/20 0.56
BCHE P06276 4/20 0.55
ACHE P22303 4/20 0.55
MEN1 O00255 3/20 0.55
ALOX5 P09917 1/20 0.55
ALDH1A1 P00352 2/20 0.54
TSHR P16473 2/20 0.54
GAA P10253 1/20 0.54
NFKB1 P19838 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
MAPT P10636 1/20 0.54
MAPK1 P28482 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
HSD17B10 Q99714 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6100235 0.92 BCHE (0.65) KMT2ASMN1; SMN2LMNAHTTTRPV1
SCHEMBL6101644 0.87 SMN1; SMN2 (0.64) KMT2ASMN1; SMN2LMNAHTTUSP2
SCHEMBL6098671 0.85 SMN1; SMN2 (0.57) KMT2ASMN1; SMN2LMNAHTTUSP2
SCHEMBL27536028 0.85 SMN1; SMN2 (0.57) KMT2ASMN1; SMN2LMNAHTTUSP2
SCHEMBL6100978 0.85 KDM4E (0.65) KMT2ASMN1; SMN2LMNAHTTUSP2
SCHEMBL6101354 0.84 MAPT (0.56) KMT2ASMN1; SMN2LMNAHTTUSP2
SCHEMBL6101360 0.84 MAPT (0.56) KMT2ASMN1; SMN2LMNAHTTUSP2
SCHEMBL6098990 0.83 SMN1; SMN2 (0.60) KMT2ASMN1; SMN2LMNAHTTUSP2
SCHEMBL6097758 0.83 LMNA (0.55) KMT2ASMN1; SMN2LMNAHTTTRPV1
SCHEMBL6100933 0.83 SMN1; SMN2 (0.63) KMT2ASMN1; SMN2LMNAHTTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7084176-B2 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2006-08-01 US claimed
US-20040248983-A1 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-09 US claimed
EP-1403235-A1 N-ARYLPHENYLACETAMIDE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME Dainippon Pharmaceutical Co., Ltd. (JP) 2004-03-31 EP claimed
US-7084176-B2 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2006-08-01 US disclosed
US-20040248983-A1 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-09 US disclosed
EP-1403235-A1 N-ARYLPHENYLACETAMIDE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME Dainippon Pharmaceutical Co., Ltd. (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248983-A1 N-arylphenylacetamide derivatives and medicinal compositions containing the same HRH2, CCR8, CYP2C8 KMT2A 1631/4885SMN1; SMN2 2474/4885LMNA 3086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.